Trials / Completed
CompletedNCT05202405
A Study to Evaluate the Safety and Pharmacokinetics of AD-221 Compared to Coadministration of AD-221A and AD-221B
An Open-label, Randomized, Single-dose, 2-sequence, 2-period, Crossover, Phase 1 Study to Evaluate the Safety and Pharmacokinetics of AD-221 Compared to Coadministration of AD-221A and AD-221B in Healty Adult Volunteers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 64 (actual)
- Sponsor
- Addpharma Inc. · Industry
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Accepted
Summary
Primary endpoint of this study is to evaluate the pharmacokinetic characteristics of AD-221 in healthy male subjects.
Detailed description
The purpose of this study is to evaluate the pharmacokinetic characteristics and safety profiles of AD-221 compared with coadministration AD-221A and AD-221B in healthy male subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AD-221 | AD-221 Oral Tablet |
| DRUG | AD-221A and AD-221B | AD-221A Oral Tablet + AD-221B Oral Tablet |
Timeline
- Start date
- 2022-01-05
- Primary completion
- 2022-03-04
- Completion
- 2022-03-04
- First posted
- 2022-01-21
- Last updated
- 2022-07-20
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT05202405. Inclusion in this directory is not an endorsement.